Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17047210 | 1.00 | MIF (0.61) | MIFKMT2AMEN1CYP2C19HIF1A | |
| SCHEMBL831691 | 1.00 | MIF (0.61) | MIFKMT2AMEN1CYP2C19HIF1A | |
| SCHEMBL1444112 | 0.83 | CYP2C19 (0.46) | MIFKMT2ACYP2C19HIF1ALMNA | |
| SCHEMBL2300536 | 0.82 | CYP2C19 (0.64) | KMT2ACYP2C19HIF1AMAPTCYP1A2 | |
| SCHEMBL167044 | 0.82 | CYP2C19 (0.64) | KMT2ACYP2C19HIF1AMAPTCYP1A2 | |
| SCHEMBL2295046 | 0.82 | CYP2C19 (0.64) | KMT2ACYP2C19HIF1AMAPTCYP1A2 | |
| SCHEMBL1585458 | 0.81 | CYP2C19 (0.44) | MIFKMT2AMEN1CYP2C19HIF1A | |
| SCHEMBL24020497 | 0.81 | MIF (0.66) | MIFKMT2AMEN1CYP2C19HIF1A | |
| SCHEMBL8476286 | 0.81 | CYP2C19 (0.68) | MIFKMT2AMEN1CYP2C19HIF1A | |
| SCHEMBL987076 | 0.81 | MIF (0.66) | MIFKMT2AMEN1CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071068-B2 | Sustained release oral dosage forms of an R-baclofen prodrug | XENOPORT, INC. (US) | 2018-09-11 | — | — | US | claimed |
| EP-2117517-B1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF A PRODRUG OF R-BACLOFEN AND METHODS OF TREATMENT | XENOPORT INC (US) | 2011-06-01 | — | — | EP | claimed |
| US-20100255093-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG | XENOPORT, INC. (US) | 2010-10-07 | — | — | US | claimed |
| US-20100137442-A2 | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment | XENOPORT, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-20090197958-A1 | Sustained Release Particulate Oral Dosage Forms of (R) Baclofen and Methods of Treatment | XENOPORT, INC. (US) | 2009-08-06 | — | — | US | claimed |
| US-20080206332-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF A PRODRUG OF R-BACLOFEN AND METHODS OF TREATMENT | WILSHIRE PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | claimed |
| US-10071068-B2 | Sustained release oral dosage forms of an R-baclofen prodrug | XENOPORT, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| EP-2117517-B1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF A PRODRUG OF R-BACLOFEN AND METHODS OF TREATMENT | XENOPORT INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100255093-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG | XENOPORT, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100137442-A2 | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment | XENOPORT, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20090197958-A1 | Sustained Release Particulate Oral Dosage Forms of (R) Baclofen and Methods of Treatment | XENOPORT, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20080206332-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF A PRODRUG OF R-BACLOFEN AND METHODS OF TREATMENT | WILSHIRE PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137442-A2 | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment | GABBR2, GABBR1, GABRB2 | MIF 3910/4885KMT2A 4184/4885MEN1 2287/4885 |
| US-20080206332-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF A PRODRUG OF R-BACLOFEN AND METHODS OF TREATMENT | GABBR2, GABBR1, GABRB2 | MIF 4208/4885KMT2A 3861/4885MEN1 1999/4885 |
| US-20090197958-A1 | Sustained Release Particulate Oral Dosage Forms of (R) Baclofen and Methods of Treatment | GABBR2, GABBR1, GABRB2 | MIF 4029/4885KMT2A 4008/4885MEN1 2074/4885 |
| US-10071068-B2 | Sustained release oral dosage forms of an R-baclofen prodrug | GABRB2, GABRB3, GABBR2 | MIF 4039/4885KMT2A 3441/4885MEN1 2120/4885 |
| US-20100255093-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG | GABRB2, GABRB3, GABBR2 | MIF 4039/4885KMT2A 3441/4885MEN1 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.